| Serial Number | 79437944 |
| Word Mark | TCANCER |
| Filing Date | Thursday, April 24, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, April 13, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 5, 2026 |
| Pseudo Mark | T CANCER |
| Goods and Services | Chemical products in the nature of chemical reagents for medical diagnosis; diagnostic preparations for medical use through using t-cell receptors (tcrs); diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations; diagnostic reagents for medical and veterinary use in in vitro diagnosis; diagnostic substances for medical use; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, individual medical diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, tumour identification; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection in oncology; diagnostic test reagents comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection for veterinary use; indicators for medical diagnosis, namely, diagnostic preparations for medical use in vivo diagnosis; medical diagnostic reagents; medical preparations for the treatment of cancer; pharmaceutical drugs in the nature of preparations for the treatment and prevention of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment and prevention of cancer; pharmaceutical preparations for diagnosis, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for diagnostic purposes, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for individual medical diagnosis, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for medical purposes for the treatment and prevention of cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in cancer diagnosis; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for individual medical diagnosis in the nature of disease detection of cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in oncology for testing of bodily fluids for use in cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer; pharmaceutical preparations for suppressing tumours; pharmaceutical preparations, namely, protein arrays for medical diagnosis purposes for the diagnosis of diseases; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for treating cancer; pharmaceutical products, medical and veterinary preparations, namely, diagnostic preparations for medical or veterinary purposes; pharmaceuticals products for the treatment of cancer; pharmaceutical products for treating cancer; preparations for medical diagnosis, namely, diagnostic preparations for medical use in vivo diagnosis; reactants for medical diagnosis, namely, diagnostic preparations for medical use in in vivo diagnosis; reagents and preparations for use in the nature of diagnostic test reagents for medical purposes; reagents for diagnostic tests for medical use; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for profiling, in particular genomic and proteomic profiling, for use in the selection of therapeutics for cancer patients; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for the diagnosis of diseases in the nature of cancer; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptors (tcrs) for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptors (tcrs) for oncological purposes for treating cancer; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptor (tcr) clusters for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptor (tcr) clusters for oncological purposes for treating cancer; tumour suppressing agents; immunomodulators, namely, pharmaceutical preparations for treatment of cancer; immunostimulants; immunotherapeutic agents, namely, pharmaceutical preparations for treatment of cancer; pharmaceutical products in the nature of preparations for the treatment of autoimmune diseases and autoimmune disorders, pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of immune system related disorders |
| Goods and Services | Maintenance of data in computer databases featuring medical patient information; maintenance of data in computer databases featuring oncological information; maintenance of data in medical computer databases; maintenance of data in computer databases |
| Goods and Services | Healthcare services, namely, computerised medical evaluation and diagnostic services in the fields of immunology, oncology, infectiology and vaccines; healthcare services, namely, computerised medical diagnostic services in the fields of immunology, oncology, infectiology and vaccines |
| Goods and Services | Blood analysis services for scientific purposes; development of database services featuring medical patient information; development of database services featuring oncological information; development of database services featuring sequenced t-cell receptors (tcrs); development of medical database services; development of database services; development of pharmaceutical preparations and medicines; research laboratory services in the medical field; maintenance of online databases for others; medical research in the field of immunology, oncology, infectiology and vaccines; medical research services, namely, performing analyses for medical research; performing chemical analyses; platform as a service (PAAS) featuring computer software platforms for use in database management and t-cell receptor (tcr) identification and characterisation; research and development of pharmaceutical preparations for treating malignant tumours; research of pharmaceuticals; research services in the field of medical analyses and diagnostics; scientific research and development in identification of tumour antigens; scientific research and development in the field of immunology, oncology, infectiology and vaccines; scientific research and development in the field of t-cell receptors (tcrs); scientific research and development; software as a service (SAAS) featuring software for database management and use in t-cell receptor (tcr) identification and characterisation; scientific research and development services for medical and pharmaceutical purposes in the fields of immunology, oncology, infectiology and vaccines; research and development services in connection with pharmaceutical and medical preparations, medicine and pharmaceuticals in the fields of immunology, oncology, infectiology and vaccines; computerised medical evaluation and diagnostic services in the nature of medical research services in the fields of immunology, oncology, infectiology and vaccines |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 27, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 27, 2025 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 27, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 27, 2025 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | HS Diagnomics GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 27 - NOT AVAILABLE |
| Address | DE |
| Event Date | Event Description |
| Thursday, November 27, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Tuesday, December 2, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, December 2, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, December 3, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, December 10, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, December 11, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Sunday, January 18, 2026 | REFUSAL PROCESSED BY MPU |
| Sunday, January 18, 2026 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, February 5, 2026 | REFUSAL PROCESSED BY IB |
| Wednesday, April 1, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, April 1, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 1, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, April 3, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 15, 2026 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, April 15, 2026 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |